Cabaletta Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cabaletta Bio (CABA).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+1348.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 1, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$16
Aug 14, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$4→$3
May 15, 2026	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$2→$4
May 4, 2026	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$30
Mar 24, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$14→$13
Mar 24, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$15→$16
Oct 31, 2025	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$15→$30
Oct 10, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$16
Sep 5, 2025	Cantor Fitzgerald	Josh Schimmer	Maintained	Overweight	$15
Aug 14, 2025	Citigroup	Samantha Semenkow	PT Cut	Buy	$13→$10
Aug 8, 2025	Guggenheim	Yatin Suneja	PT Cut	Buy	$25→$15
Aug 8, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$3→$2
Jun 11, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$25
May 16, 2025	Citigroup	Samantha Semenkow	PT Cut	Buy	$17→$13
May 16, 2025	Guggenheim	Yatin Suneja	PT Raise	Buy	$23→$25
May 15, 2025	Guggenheim	Yatin Suneja	PT Raise	Buy	$23→$25
Apr 1, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$6→$3
Apr 1, 2025	Guggenheim	Yatin Suneja	Maintained	Buy	$23
Apr 1, 2025	UBS	Trung Huynh	PT Cut	Buy	$10→$7
Apr 1, 2025	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$30→$22

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.

Benzinga Newsdesk

Cabaletta Bio Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cabaletta Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

People Also Watch

People Also Watch

Cabaletta Bio Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cabaletta Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

PROWells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

PROWells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

PROCantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

PROMorgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

PROGuggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16